Intravenous immune globulin therapy for early-onset sepsis in premature neonates

Weisman, Leonard E.; Stoll, Barbara J.; Kueser, Thomas J.; Rubio, Thomas; Frank, Claudia; Heiman, Howard S.; Subramanian, K. N. Siva; Hankins, Charles T.; Anthony, Bascom F.; Cruess, David F.; Hemming, Val G.; Fischer, Gerald W.

doi:10.1016/s0022-3476(05)81802-5

Cited by 85 publications

(37 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Foram encontrados 53 estudos, dos quais nove [13][14][15][16][17][18][19][20][21] foram selecionados para leitura do texto completo. Outros dois estudos foram selecionados para leitura do texto completo através de busca manual 22,23 .…”

Section: Resultsunclassified

Adjuvant use of intravenous immunoglobulin in the treatment of neonatal sepsis: a systematic review with a meta-analysis

Franco¹,

Torrico²,

Moreira³

et al. 2012

J Pediatr (Rio J)

View full text Add to dashboard Cite

Objective: To evaluate whether intravenous immunoglobulin reduces mortality and length of hospital stay in the treatment of neonatal sepsis. Sources:The MEDLINE database was searched. The keywords were combined using the following search strategy: [(sepsis OR shock, septic OR infection) AND immunoglobulins, intravenous] AND infant, newborn. Only randomized clinical trials (RCTs) showing good methodological quality and assessing the effect of adjuvant intravenous immunoglobulin in the treatment of neonatal sepsis were selected for inclusion and data analysis.Summary of the findings: Seven RCTs were selected. All of them evaluated the mortality rate, including 3,756 patients. The global effect of this outcome showed no statistically significant difference between the groups. Only five studies evaluated the mean length of hospital stay, including 3,672 patients. Although there is a statistically significant reduction of 1.24 days in the length of hospital stay with the use of intravenous immunoglobulin, such difference is clinically irrelevant and its high cost does not warrant its routine use in medical practice. The data reported in the present review contradict the review by Ohlsson et al., which was updated in 2010 and showed significant benefit with the use of intravenous immunoglobulin on both outcomes. Conclusions:We concluded that the use of adjuvant intravenous immunoglobulin shows no benefit regarding mortality, whereas the reduction in the length of hospital stay is irrelevant. J Pediatr (Rio J). 2012;88(5):377-83:Intravenous immunoglobulin, neonatal sepsis, septic shock, sepsis, infection, newborn infant. ResumoObjetivo: Avaliar se a imunoglobulina endovenosa reduz a mortalidade e o tempo de internação no tratamento da sepse neonatal. Fonte dos dados: 377378 Jornal de Pediatria -Vol. 88, N° 5, 2012 Uso da imunoglobulina endovenosa na sepse neonatal -Franco AC et al.

show abstract

Section: Resultsunclassified

Adjuvant use of intravenous immunoglobulin in the treatment of neonatal sepsis: a systematic review with a meta-analysis

Franco¹,

Torrico²,

Moreira³

et al. 2012

J Pediatr (Rio J)

View full text Add to dashboard Cite

show abstract

“…The test of heterogeneity was not significant. One study (38) reported a significant reduction in mortality, three studies reported a positive trend (31,33,42), and two studies (34,40) showed no effect. One trial (36) showed a duplication of mortality; one neonate died in the control group and two in the treatment group.…”

Section: Use Of Immunoglobulins In the Treatment Of Neonatal Sepsismentioning

confidence: 99%

“…The study of El Nawawy (32) reported a significant reduction of mortality, the other four a positive trend (35,37,39,41). Polyvalent immunoglobulin preparations containing only IgG were evaluated in seven trials (31,33,34,36,38,40,42) involving 358 patients. The cumulative dose of IgG was 0.5-3 g/kg birth weight.…”

Section: Use Of Immunoglobulins In the Treatment Of Neonatal Sepsismentioning

confidence: 99%

Immunoglobulins in the Prevention and Treatment of Neonatal Sepsis

Resch¹,

Resch²

2013

Neonatal Bacterial Infection

View full text Add to dashboard Cite

“…Intravenous immunoglobulin (IVIG) has been widely used prophylactically in premature neonates at risk for septicaemia [13][14][15][16][17][18], and actually has been incorporated into the treatment regimen of bacterial infections of neonates [19][20][21][22][23]. IVIG has been shown to yield a favourable clinical outcome in certain neonates [13][14][15][19][20][21], but several groups have suggested that IVIG has neither prophylactic nor therapeutic effect on such neonates [16][17][18]22,23]. Although bacterial clearance by IVIG therapy has been investigated in vivo [24,25], there has been no study of PMN functions associated with IVIG therapy in vivo and in vitro.…”

Section: Introductionmentioning

confidence: 99%

Effect of immunoglobulin therapy on phagocytosis by polymorphonuclear leucocytes in whole blood of neonates

Fujiwara

Taniuchi

Hattori

et al. 1997

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYThere has been some disagreement as to the clinical effect of intravenous immunoglobulin (IVIG) therapy on neonatal bacterial infections. We therefore evaluated the effect of IVIG therapy on neonatal polymorphonuclear leucocyte (PMN) functions by monitoring phagocytosis and hydrogen peroxide (H 2 O 2 ) production. Subjects were 10 mature neonates who had normal plasma levels (i.e. equal to adult plasma levels) of IgG and nine premature neonates who had lower plasma levels of IgG. Phagocytosis by PMN was measured using flow cytometric analysis of whole blood. Addition of g-globulin to the whole blood of mature neonates increased phagocytosis, but not significantly. Higher doses of added g-globulin (> 2·0 mg/ml, the concentration was expressed as that in the final reaction volume) decreased phagocytosis to under baseline level. In premature neonates addition of g-globulin increased phagocytosis and the significant maximum effect was observed with 0·5 mg/ml of the additional g-globulin.Higher doses of additional g-globulin (2·5 mg/ml) decreased phagocytosis to baseline level. Phagocytosis in four mature and four premature neonates was compared before and after 1 g/kg of IVIG therapy. Phagocytosis in mature neonates after IVIG therapy did not change compared with the pretreatment level. On the other hand, phagocytosis in premature neonates after IVIG therapy significantly increased compared with its pretreatment level. In both mature and premature neonates H 2 O 2 production following phagocytosis varied in parallel with changes of phagocytosis. The patterns of H 2 O 2 production following phagocytosis were essentially similar to those observed with phagocytosis. The above results are expected to form the basis for a rational indication for IVIG therapy against bacterial infections in neonates with low plasma IgG levels.

show abstract

Intravenous immune globulin therapy for early-onset sepsis in premature neonates

Cited by 85 publications

References 37 publications

Adjuvant use of intravenous immunoglobulin in the treatment of neonatal sepsis: a systematic review with a meta-analysis

Adjuvant use of intravenous immunoglobulin in the treatment of neonatal sepsis: a systematic review with a meta-analysis

Immunoglobulins in the Prevention and Treatment of Neonatal Sepsis

Effect of immunoglobulin therapy on phagocytosis by polymorphonuclear leucocytes in whole blood of neonates

Contact Info

Product

Resources

About